Literature DB >> 3973621

Cerebrospinal fluid vasopressin in neurological and psychiatric disorders.

P S Sørensen, A Gjerris, M Hammer.   

Abstract

Vasopressin was determined in CSF and plasma of 243 patients with different neurological and psychiatric disorders, including control patients. CSF vasopressin was significantly higher in patients with high pressure hydrocephalus, intracranial tumour, benign intracranial hypertension, intracranial haemorrhage, ischaemic stroke, and craniocerebral trauma. In patients with primary degenerative dementia, CSF vasopressin was lower than in control patients. Among patients with psychiatric disorders, CSF vasopressin was increased in manic patients, while in patients with depression CSF concentration of this hormone did not differ from that found in controls. However, an increase in CSF vasopressin level was found in patients recovering from a depression. The clinical significance of changes in CSF vasopressin concentrations in groups of patients with neurological and psychiatric disorders is still unknown.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3973621      PMCID: PMC1028182          DOI: 10.1136/jnnp.48.1.50

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  37 in total

1.  Effect of vasopressin on intracranial pressure of rabbit.

Authors:  T Noto; T Nakajima; Y Saji; Y Nagawa
Journal:  Endocrinol Jpn       Date:  1978-12

2.  Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat.

Authors:  R M Buijs; D F Swaab; J Dogterom; F W van Leeuwen
Journal:  Cell Tissue Res       Date:  1978-01-31       Impact factor: 5.249

3.  Regulation of brain water permeability by centrally-released vasopressin.

Authors:  M E Raichle; R L Grubb
Journal:  Brain Res       Date:  1978-03-17       Impact factor: 3.252

4.  Influence of vasopressin on learning and memory.

Authors:  J J Legros; P Gilot; X Seron; J Claessens; A Adam; J M Moeglen; A Audibert; P Berchier
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

5.  The hypothalamo-choroidal tract. I. Immunohistochemical demonstration of neurophysin pathways to telencephalic choroid plexuses and cerebrospinal fluid.

Authors:  M S Brownfield; G P Kozlowski
Journal:  Cell Tissue Res       Date:  1977-03-01       Impact factor: 5.249

6.  Radioimmunoassay of 8-arginine-vasopressin (antidiuretic hormone) in human plasma.

Authors:  M Hammer
Journal:  Scand J Clin Lab Invest       Date:  1978-12       Impact factor: 1.713

7.  The resistance to cerebrospinal fluid absorption in humans. A method of evaluation by lumbo-ventricular perfusion, with particular reference to normal pressure hydrocephalus.

Authors:  S E Børgesen; F Gjerris; S C Srensen
Journal:  Acta Neurol Scand       Date:  1978-01       Impact factor: 3.209

8.  Vasopressin in human cerebrospinal fluid.

Authors:  J S Jenkins; H M Mather; V Ang
Journal:  J Clin Endocrinol Metab       Date:  1980-02       Impact factor: 5.958

9.  The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale.

Authors:  P Bech; T G Bolwig; P Kramp; O J Rafaelsen
Journal:  Acta Psychiatr Scand       Date:  1979-04       Impact factor: 6.392

10.  Vasopressin in affective illness.

Authors:  P W Gold; F K Goodwin; V I Reus
Journal:  Lancet       Date:  1978-06-10       Impact factor: 79.321

View more
  18 in total

1.  Multiple sites of vasopressin synthesis in the injured brain.

Authors:  Joanna Szmydynger-Chodobska; Brian J Zink; Adam Chodobski
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-20       Impact factor: 6.200

2.  Vasopressin amplifies the production of proinflammatory mediators in traumatic brain injury.

Authors:  Joanna Szmydynger-Chodobska; Leora M Fox; Kirsten M Lynch; Brian J Zink; Adam Chodobski
Journal:  J Neurotrauma       Date:  2010-08       Impact factor: 5.269

3.  Intracerebroventricular vasopressin reduces CSF absorption rate in the conscious goat.

Authors:  J R Seckl; S L Lightman
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

4.  Cerebrospinal fluid neurohypophysial peptides in benign intracranial hypertension.

Authors:  J Seckl; S Lightman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-12       Impact factor: 10.154

Review 5.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

6.  Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury.

Authors:  Christina R Marmarou; Xiuyin Liang; Naqeeb H Abidi; Shanaz Parveen; Keisuke Taya; Scott C Henderson; Harold F Young; Aristotelis S Filippidis; Clive M Baumgarten
Journal:  Brain Res       Date:  2014-06-13       Impact factor: 3.252

7.  Vasopressin V1a Receptors Regulate Cerebral Aquaporin 1 after Traumatic Brain Injury.

Authors:  Katrin Rauen; Viorela Pop; Raimund Trabold; Jerome Badaut; Nikolaus Plesnila
Journal:  J Neurotrauma       Date:  2019-12-04       Impact factor: 5.269

8.  Plasma and cerebrospinal fluid arginine vasopressin in patients with and without fever.

Authors:  P M Sharples; J R Seckl; D Human; S L Lightman; D B Dunger
Journal:  Arch Dis Child       Date:  1992-08       Impact factor: 3.791

9.  Cerebral microvascular endothelial cell Na/H exchange: evidence for the presence of NHE1 and NHE2 isoforms and regulation by arginine vasopressin.

Authors:  Tina I Lam; Phyllis M Wise; Martha E O'Donnell
Journal:  Am J Physiol Cell Physiol       Date:  2009-05-20       Impact factor: 4.249

10.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.